阿昔单抗/肝素方案用于肝素诱导血小板减少症患者LVAD植入
该研究描述了在肝素诱导血小板减少症(HIT)患者中行左心室辅助装置(LVAD)植入时使用阿昔单抗联合肝素的抗凝方案。6例患者采用该方案,术中无血栓栓塞并发症,1例因出血再探查,初步结果提示方案可行且安全。
要点
- 阿昔单抗负荷0.25 mg/kg后持续输注0.125 μg·kg-1·min-1,维持ACT≥400秒。
- 6例LVAD植入患者中无血栓栓塞并发症,1例因出血再探查。
- 术后中位第3天重启阿加曲班抗凝,第5天启动华法林。
核心结论
- 首次报告阿昔单抗/肝素方案用于HIT患者LVAD植入,初步结果提示可行且安全。
研究设计与样本
- 单中心回顾性描述性研究,纳入6例接受LVAD植入的HIT患者。
主要发现
- 6例中4例确诊HIT、2例疑似但术后阴性,无血栓栓塞并发症。
- 1例因出血需再次开胸探查并临时右心室辅助支持。
- 术后中位第3天(范围1-6天)重启阿加曲班,第5天(范围3-12天)启动华法林。
- 中位ICU停留9天(范围5-76天),住院22天(范围18-132天)。
- 1例HeartMate XVE交换为HeartMate II后行心脏移植,另1例心肌恢复后移除装置,余4例存活带装置支持。
关键数值与推荐
- 阿昔单抗负荷剂量0.25 mg/kg,随后持续输注0.125 μg·kg-1·min-1直至体外循环结束。
- 全剂量肝素追加维持活化凝血时间≥400秒。
- 鱼精蛋白逆转肝素后15分钟停止阿昔单抗输注并输注血小板。
临床怎么用
- 对HIT患者行LVAD植入时可考虑阿昔单抗/肝素方案作为抗凝选择。
- 术中需监测ACT并维持≥400秒,术后及时过渡至阿加曲班和华法林。
局限性
- 样本量仅6例,为单中心初步经验,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal anticoagulation strategy remains uncertain in patients with heparin-induced thrombocytopenia (HIT) and undergoing left ventricular assist device (LVAD) implantation. We describe our protocol of abciximab and heparin in these patients. METHODS: Our protocol is to administer abciximab, 0.25 mg/kg loading dose, followed by continuous infusion of 0.125 μg · kg-1 · min-1 throughout cardiopulmonary bypass. Full-dose heparin is then given with subsequent additional doses to maintain an activated clotting time of 400 seconds or longer. The abciximab infusion is stopped 15 minutes after heparin reversal with protamine, and platelets are transfused. RESULTS: Six patients underwent LVAD implantation with this protocol in our program. HIT was confirmed in 4 patients was suspected in 2, which was negative after the operation. One patient received a HeartMate XVE (Thoratec Corp, Pleasanton, CA) and the others received HeartMate II (Thoratec Corp). There were no thromboembolic complications. One patient required chest reexploration for bleeding and temporary right VAD support. Postoperative anticoagulation with argatroban was restarted on median postoperative day 3 (range, days 1 to 6) and warfarin was started on day 5 (range, days 3 to 12). Median postoperative intensive care unit stay was 9 days (range, 5 to 76 days), and hospital stay was 22 days (range, 18 to 132 days). After the initial LVAD implantation, 1 patient required HeartMate XVE LVAD exchange to HeartMate II and subsequent heart transplant, both of which were performed with the abciximab/heparin protocol. A HeartMate II device was explanted in another patient after myocardial recovery. The remaining 4 patients are alive on device support. CONCLUSIONS: This is the first report of a novel abciximab/heparin protocol for LVAD implantation in patients with HIT. The preliminary results suggest the feasibility and safety of this protocol.
引用
- Lee CL, Colombo PC, Eisenberger A, et al. Abciximab/Heparin Therapy for Left Ventricular Assist Device Implantation in Patients With Heparin-Induced Thrombocytopenia. Ann Thorac Surg. 2017. PMID: 28987395. doi:10.1016/j.athoracsur.2017.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。